The efficacy of remifentanil on the BIS values of patients who are treated with mECT:open-labeled single center non-randomized cross-over trial

The efficacy of remifentanil on the BIS values of patients who are treated with mECT:open-labeled single center non-randomized cross-over trial - The efficacy of remifentanil on the BIS values of patients who are treated with mECT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010858

Enrollment

Registered

2013-06-04

Start date

2013-06-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychiatric disorders

Interventions

In the interventional treatments, patients are sedated with remifentanil 1mcg/kg in addition to thiopental 3mg/kg. In the control treatments, patients are sedated with thiopental 3mg/kg.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The study population consists of patients whose BIS values before the electrical stimuli are more than 60, when they are treated with Thymatron&#174; for the first time.

Exclusion criteria

Exclusion criteria: ASA PS 4 or 5 history of ischemic heart disease history of heart disease as harmful as ischemic disease allergies or contraindications to medications used in the trial

Design outcomes

Primary

Measure	Time frame
the BIS value before the electrical stimulus, the duration of the convulsion	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026